Noerr advises banks on successful capital increase at Vivoryon Therapeutics AG

Noerr has advised the syndicate banks NIBC Bank and ODDO BHF in connection with a capital increase with subscription rights by Vivoryon Therapeutics AG. Vivoryon raised funds of €43 million from the rights offering to existing shareholders and a subsequent private placement with selected European investors. The proceeds from the issue will be used to finance a clinical trial in Europe. The company’s activities focus mainly on innovative therapeutic solutions for treating neurological illnesses, including Alzheimer’s.

In total, around 7.67 million new shares were placed at a price of €5.61 per share and admitted to existing trading on Euronext Amsterdam. One of the new investors is MorphoSys AG.

NIBC Bank and ODDO BHF acted as joint global coordinators and joint bookrunners.

Advisors to NIBC Bank and ODDO BHF AG: Noerr LLP

Dr Holger Alfes (lead), Dr Julian Schulze De la Cruz (both Capital Markets, Frankfurt), Professor Sebastian Wündisch (IP, Dresden), Associates: Dominique Stütz (Lead Associate, Capital Markets, Frankfurt), Anne-Kristin Schiller (Capital Markets, New York), Lisa Schmitt (Corporate, Frankfurt), Susann Jahn (Digital Business, Dresden), Selina Brose (Corporate, Frankfurt)